tongxinluo
Jump to navigation
Jump to search
Introduction
a traditional Chinese medicine compound
Indications
- may improve 30 day & 1 year outcomes after STEMI[1]
- initially approved in China for angina pectoris & ischemic stroke in 1996
* may improve myocardial microvascular perfusion in patients with STEMI post percutaneous coronary intervention[1]
Dosage
- 12 months of oral therapy for STEMI
- loading dose of 2.08 g followed by maintenance dose of 1.04 g TID for 12 months
Mechanism of action
- composed of powders & extracts from multiple plant & insect products
- exact mechanism of action is unclear
- it has been suggested that peoniflorin,ginsenoside Rg1 & ginsenoside Rb1 contained in tongxinluo have potential cardioprotective effects[1]
- in vitro reduces endothelial cell apoptosis via autophagy induction[1]
More general terms
References
- ↑ 1.0 1.1 1.2 1.3 1.4 1.5 Yang Y, Li X, Chen G et al Traditional Chinese Medicine Compound (Tongxinluo) and Clinical Outcomes of Patients With Acute Myocardial Infarction. The CTS-AMI Randomized Clinical Trial. JAMA. 2023;330(16):1534-1545 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37874574 https://jamanetwork.com/journals/jama/fullarticle/2811016
Bach RG Traditional Chinese Medicine Meets Evidence-Based Medicine in the Acutely Infarcted Heart. JAMA. 2023;330(16):1529-1530 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37874582 https://jamanetwork.com/journals/jama/fullarticle/2811037
Curfman G Traditional Chinese Medicine for ST-Segment Elevation Myocardial Infarction. JAMA. 2023;330(16):1546 PMID: https://www.ncbi.nlm.nih.gov/pubmed/37874581 https://jamanetwork.com/journals/jama/fullarticle/2811036